- Minjuvi is an important new therapeutic option for eligible patients with DLBCL in Canada, addressing an urgent unmet medical need - This marks the first marketing authorization by Health Canada for Incyte since establishing Incyte Biosciences Canada in April 2020 MONTREAL, Aug. 24, 2021 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health Canada has granted a Notice of Compliance with conditions for Minjuvi (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT). Incyte Biosciences Canada Logo (CNW Group/Incyte Biosciences Canada) "The data from L-MIND demonstrated that eligible patients treated with tafasitamab and lenalidomide had a high likelihood of benefit, which was durable in many cases," said Dr.
Recent Comments